ViiV Healthcare Announces Data Demonstrating 2-Drug Regimen DOVATO Is As Effective As 3-Drug Regimen BIKTARVY For Maintenance Therapy Of HIV-1

Author: Benzinga Newsdesk | July 31, 2024 08:24am

• Largest head-to-head randomized clinical trial between DTG/3TC and BIC/FTC/TAF, conducted by SEIMC-GeSIDA Foundation (FSG) showed DTG/3TC demonstrated non-inferior efficacy compared to BIC/FTC/TAF as a switch regimen for virologically-suppressed adults living with HIV over 48 weeks of therapy.
• DTG/3TC-treated individuals had significantly less weight gain compared to those randomized to BIC/FTC/TAF.
• In 2022, the Canadian HIV incidence rate grew by 15% in comparison to 2020, a total of 1,848 new cases. 1
• According to the latest surveyed data, there is an estimated 65,270 Canadians living with HIV. 1

MONTREAL, July 31, 2024 /CNW/ - ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, announced the 48-week findings from PASO DOBLE (GeSIDA 11720 study), the largest head-to-head, phase IV randomized clinical trial (RCT) investigating the 2-drug regimen DOVATO (dolutegravir/lamivudine [DTG/[3TC]) compared to the 3-drug regimen BIKTARVY (bictegravir/emtricitabine]/tenofovir alafenamide fumarate [BIC/FTC/TAF]) for the treatment of HIV-1 in people who are virologically suppressed and who could benefit from treatment optimization.2  

Posted In: PFE